SK Inc.

Press 2023-10-18

SK pharmteco to showcase its extensive APIs and CGT capabilities in CPHI 2023

- With a dedicated booth in the main exhibition hall, SK pharmteco solidifies its global position as the most trusted CDMO partner in the pharmaceutical industry - Appoints Chief Commercial Officer Andrew Fenny to strengthen its global marketing capabilities - Shortlisted as a finalist for the 2023 CPHI Pharma Awards in the Accelerating Innovation category

View more

Press 2023-09-20

SK pharmteco to Expand Capabilities with Acquisition of Controlling Interest in CBM

-CBM brings extensive cell and gene therapy expertise to SK pharmteco portfolio and continues SK pharmteco’s strategy to deliver end-to-end, multi-modality support for clients -SK pharmteco previously invested $350 million in CBM in 2022

View more

Press 2023-07-26

SK Inc.’s board of directors declares an interim dividend of KRW 1,500 per share

- The first interim dividend payout after Articles of Incorporation were amended to enable investors to invest after checking dividend amount - Shareholders of record as of August 10, 2023 will receive dividend payout

View more

Press 2023-06-23

SK pharmteco doubles viral vector production capacity in Europe

Yposkesi, SK pharmteco’s clinical and commercial viral vector manufacturing subsidiary for Cell and Gene Therapy, completes its second bioproduction facility and doubles its manufacturing footprint to 10,000m2, one of the largest in Europe - Operation of the second facility to kick start in 2024

View more

Press 2023-06-16

SK Inc.-SK innovation-Korea Hydro & Nuclear Power Sign MOU to Cooperate in Clean Energy Business

- Enhancing collaborative business efforts in clean energy including nuclear power, renewable energy, hydrogen and SMR, for a sustainable future - Achieving carbon neutrality through global competiveness in sustainable energy

View more

Press 2023-04-04

SK Inc.’s subsidiary Yes Power Technix renames itself to SK powertech

-Renaming reflects the company’s drive to accelerate competitiveness in SiC power semiconductor design and manufacturing after the 2022 acquisition by SK Inc. -New plant in Busan City to kick-start commercial production in April

View more

Press 2023-03-31

SK Inc. Holds Annual General Meeting (AGM) of Shareholders

“Responding to unpredictable changes and building a forward-looking portfolio”

View more

Press 2023-03-16

SK Inc. to bolster its investment in future mobility in the fast growing Southeast Asian market

SK Inc., the strategic investment holding company of South Korea’s SK Group, announced on Thursday that it has agreed to sell its entire stake in Turo, a peer-to-peer (P2P) vehicle car-sharing company, for USD 67.5 million (approximately KRW 88.1 billion). The transaction is expected to be completed in the first half of this year with SK Inc. selling its stake in Turo to existing shareholder G Squared.

View more

Press 2023-01-10

SK Inc. hosts “SK Bio Night” in San Francisco to expand global partnerships

-SK to spark innovative ideas and identify new business opportunities by presenting its global strategy and growth roadmap to over 50 partners -Newly appointed executives to lead SK’s biopharmaceutical businesses to attend the event -SK Inc. to promote the competitiveness of K-bio and provide insight into its remarkable achievements in the US, Europe and Korea markets

View more

Press 2022-12-21

SK Inc. Showcases Technologies That Will Lead to a Carbon Neutral Future at CES 2023

- SK Inc. introduces its net zero value chain, including eco-friendly, energy-saving technologies that target carbon reduction - SK Signet, Atom Power, Halio, Perfect Day Inc., and other companies in SK Inc.’s investment portfolio demonstrate key solutions to achieving net zero emissions - To help realize a net zero future, SK will also operate a ‘Sustainable Food Truck’ at CES 2023 that will provide animal-free whey protein food

View more

Press 2022-12-27

SK Inc. receives the highest ESG rating of ‘AAA’ from MSCI

- The company has been selected for the DJSI World Index for the 11th consecutive year with highest score in the Industrial Conglomerates Industry category - SK Inc. also receives A+ for the third consecutive year from the Korea Institute of Corporate Governance and Sustainability

View more

Press 2022-11-25

SK Inc. diversifies its sustainable food business, strengthening global and local partnerships

- SK Inc. invests $7 million (KRW 10 billion) in the U.S-based cell-cultivated salmon producer Wildtype expecting commercialization in 2023 - SK Inc., Perfect Day and Maeil Dairies sign an MOU to propel non-animal dairy protein business in Korea - Aju IB Investment endorses the growth potential of Meatless Farm with a $7 million (KRW 10 billion) investment in the sustainable food producer in which SK Inc. has also invested in

View more

Press 2022-10-04

SK Inc. expands CDMO capacity, accelerating its advance to the global market

SK biotech to begin annual API production of 150 tonnes with the completion of M3, its first phase of capacity addition at its Sejong plant

View more

Press 2022-07-21

SK Inc., declared an interim dividend of KRW1,500 per share

SK Inc., declared an interim dividend of KRW1,500 per share, as part of its commitment to shareholder return

View more

Press 2022-02-09

SK Inc. pays highest dividend to shareholders

- SK Inc. confirms annualized payout of KRW 8,000 (interim dividend of KRW 1,500/ year-end dividend of KRW 6,500), recording highest dividend return yet again - The company records a total dividend amount of KRW 447.6 billion, a 114% increase from KRW 208.7 billion in 2016 - The investment company partially sold shares of SK Biopharmaceuticals in 2021, reflecting the profit into the dividend - SK Inc. to continue fostering its four core businesses (advanced materials/bio/green/ digital) and shareholders-friendly management efforts

View more

Press 2022-01-12

SK Inc. becomes second-largest shareholder of the Center for Breakthrough Medicines

SK Inc. becomes second-largest shareholder of the Center for Breakthrough Medicines, a U.S.-based Cell and Gene Therapy (CGT) CDMO, accelerating its growth as a global leader in the field

View more